Abstract

BACKGROUND: Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversion.METHODS: Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, patients with AF who had a cardioversion, follow-up data and an AF diagnosis within 6 months of enrolment were identified retrospectively. Clinical outcomes were compared for patients receiving a NOAC or VKA for 1year following cardioversion.RESULTS: Among 13004 patients with AF, 2260 (17%) underwent cardioversion. 1613 met the inclusion criteria for this analysis. At the time of cardioversion, 283 (17.5%) were receiving a VKA and 1330 (82.5%) a NOAC. A transoesophageal echocardiogram (TOE) was performed in 403 (25%) cardioversions. The incidence of stroke/transient ischaemic attack (TIA) at 30 days was the same for patients having (3.04 per 100 patient-years) or not having (3.04 per 100 patient-years) a TOE (p=0.99). There were no differences in the incidence of death (HR 1.19, 95%CI 0.62 to 2.28, p=0.61), cardiovascular hospitalisation (HR 1.02, 95%CI 0.76 to 1.35, p=0.91), stroke/TIA (HR 1.18, 95%CI 0.30 to 4.74, p=0.81) or bleeding-related hospitalisation (HR 1.29, 95%CI 0.66 to 2.52, p=0.45) at 1year for patients treated with either a NOAC or VKA.CONCLUSIONS: Cardioversion was a low-risk procedure for patients treated with NOAC, and there were statistically similar rates of stroke/TIA 30 days after cardioversion as for patients treated with VKA. There were no statically significant differences in death, stroke/TIA or major bleeding at 1year among patients treated with NOAC compared with VKA after cardioversion.

View details for DOI 10.1136/heartjnl-2019-316315

View details for PubMedID 32591363